Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
ADC Innovation | Pyxis Oncology's novel antibody-drug conjugate technology shows promise in early trials, demonstrating efficacy across multiple tumor types |
Clinical Progress | Explore PYX-201's development, showcasing a favorable safety profile and potential advantages over existing ADCs in the competitive oncology landscape |
Market Potential | Analyst price targets range from $7 to $13, suggesting significant upside potential if upcoming data readouts prove successful |
Strategic Outlook | Delve into Pyxis's future prospects, balancing its innovative approach against financial constraints and intense market competition in cancer therapeutics |
Metrics to compare | PYXS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPYXSPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.7x | −4.7x | −0.5x | |
PEG Ratio | 0.04 | −0.04 | 0.00 | |
Price/Book | 0.6x | 4.0x | 2.6x | |
Price / LTM Sales | - | 81.6x | 3.3x | |
Upside (Analyst Target) | - | 174.6% | 43.5% | |
Fair Value Upside | Unlock | 0.1% | 6.9% | Unlock |